CARISEL Interim Results: Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators of LA CAB + RPV

October 27-30, 2021; London, United Kingdom
Participants found LA CAB + RPV to be an acceptable, appropriate, and feasible treatment option for maintenance of HIV virologic suppression from Months 1 to 4.
Format: Microsoft PowerPoint (.ppt)
File Size: 248 KB
Released: November 2, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Perspective on ART modification to reduce CVD risk in PWH, from Dr Jens D. Lundgren and Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Released: November 29, 2021

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight, from Clinical Care Options (CCO)

person default Anonymous Patient Released: November 29, 2021

Dr Milena Murray and Clinical Care Options (CCO): Data suggests patient factors that may inform candidacy for LA CAB + RPV as a treatment option

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: November 24, 2021

Expert recap of new data on HIV drug resistance from EACS 2021, from Dr Babafemi Taiwo and Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: November 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue